We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-6.72%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$647M
AUM Growth
-$83.7M
Cap. Flow
-$10M
Cap. Flow %
-1.55%
Top 10 Hldgs %
49.16%
Holding
110
New
21
Increased
23
Reduced
14
Closed
30

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$30.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$24M
3
NVO
Novo Nordisk
NVO
+$22.8M
4
PTCT icon
PTC Therapeutics
PTCT
+$13.5M
5
GILD icon
Gilead Sciences
GILD
+$13.4M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$31.8M
2
GSK icon
GSK
GSK
+$20M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$19.3M
4
VRNT
Verint Systems
VRNT
+$15.6M
5
BLUE
bluebird bio
BLUE
+$9.54M

Sector Composition

Rank Sector Weight
1 Healthcare 74.15%
2 Technology 11.83%
3 Industrials 2.25%
4 Consumer Discretionary 1.19%
5 Communication Services 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTLA
26
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$6.97M 1.08%
+260,000
New +$7.3M
FISV
27
Fiserv Inc
FISV
$28.8B
$6.97M 1.08%
67,279
+26,914
+67% +$2.75M
PANW icon
28
Palo Alto Networks
PANW
$270B
$6.72M 1.04%
197,856
+30,000
+18% +$1.06M
SWTX
29
DELISTED
SpringWorks Therapeutics
SWTX
$6.72M 1.04%
+310,000
New +$7.33M
XCUR icon
30
Exicure
XCUR
$10.2M
$6.67M 1.03%
+17,587
New +$6.73M
FSCT
31
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
$6.59M 1.02%
173,696
+850
+0.5% +$31.1K
AUDC icon
32
AudioCodes
AUDC
$244M
$6.21M 0.96%
328,263
-127,959
-28% -$2.3M
NERV icon
33
Minerva Neurosciences
NERV
$185M
$5.91M 0.91%
95,252
+1,250
+1% +$70.8K
NEOS
34
DELISTED
Neos Therapeutics, Inc
NEOS
$5.78M 0.89%
3,908,265
+196,811
+5% +$319K
VRNT
35
DELISTED
Verint Systems
VRNT
$5.75M 0.89%
264,002
-585,098
-69% -$15.6M
ALDX icon
36
Aldeyra Therapeutics
ALDX
$92.9M
$5.63M 0.87%
1,069,089
– –
SEDG icon
37
SolarEdge
SEDG
$2.51B
$5.36M 0.83%
64,002
-108,760
-63% -$8.11M
ALLT icon
38
Allot
ALLT
$372M
$5.33M 0.82%
661,031
– –
PRQR icon
39
ProQR Therapeutics
PRQR
$243M
$5.27M 0.81%
915,000
+445,000
+95% +$3.55M
HARP
40
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$5.11M 0.79%
37,403
– –
RETA
41
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.08M 0.78%
63,269
-49,500
-44% -$4.2M
YMAB
42
DELISTED
Y-mAbs Therapeutics
YMAB
$4.95M 0.76%
190,000
– –
CHMA
43
DELISTED
Chiasma, Inc. Common Stock
CHMA
$4.9M 0.76%
+990,000
New +$5.61M
ARVN icon
44
Arvinas
ARVN
$518M
$4.42M 0.68%
205,281
– –
ARGX icon
45
argenx
ARGX
$54.6B
$4.4M 0.68%
38,581
– –
SIOX
46
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$4.32M 0.67%
668,541
– –
WIX icon
47
WIX.com
WIX
$2.3B
$4.31M 0.67%
36,890
+16,200
+78% +$2.25M
ZYME icon
48
Zymeworks
ZYME
$1.61B
$4.22M 0.65%
+170,000
New +$4.26M
KRYS icon
49
Krystal Biotech
KRYS
$10.1B
$4.08M 0.63%
117,625
– –
KRNT icon
50
Kornit Digital
KRNT
$705M
$4.05M 0.63%
131,588
-49,686
-27% -$1.48M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2019 Portfolio in Review

As of Q3 2019, Sphera Funds Management held 110 positions worth $647M, down 11% from $731M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sphera Funds Management's Q3 2019 filing shows 21 new, 23 increased, 14 reduced and 30 closed positions. Its largest new stake was Sanofi: 700,000 shares worth $32.4M. The largest sale was AstraZeneca, an estimated $31.8M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 70% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q3 2019 buy was Sanofi: 700,000 shares worth $32.4M.
  • Sphera Funds Management added most to Sarepta Therapeutics in Q3 2019, an estimated $24M increase.
  • Sphera Funds Management's biggest Q3 2019 reduction was Alexion Pharmaceuticals, cutting an estimated $19.3M.
  • Sphera Funds Management fully exited AstraZeneca in Q3 2019, selling an estimated $31.8M.
  • Sphera Funds Management's ten largest holdings make up 49% of its $647M portfolio in Q3 2019.
  • Sphera Funds Management opened 21 new positions and closed 30 in Q3 2019.
  • Sphera Funds Management's portfolio value fell 11% quarter-over-quarter to $647M.

Based on Sphera Funds Management's 13F filing for Q3 2019, filed 14 Nov 2019.